Table 1 Baseline clinical characteristics
Characteristic | |
|---|---|
Number | 59 |
Age | 71 (63–79) |
Older age (%) | 49.2 |
Sex (male, %) | 76.3 |
Etiology of ESRD (%) | |
DN | 40.7 |
NS | 23.7 |
CGN | 15.3 |
ADPKD | 1.7 |
IgAN | 5.1 |
Other or unknown | 13.6 |
Smoking history (%) | 64.4 |
DM (%) | 57.6 |
Dyslipidemia (%) | 57.6 |
Major CVD (%) | 54.2 |
IHD | 35.6 |
CHF | 13.6 |
Stroke | 8.5 |
PAD (%) | 13.6 |
RASI (%) | 52.5 |
Statin (%) | 49.1 |
Antiplatelet agents (%) | 52.5 |
Aspirin | 47.5 |
Clopidogrel | 23.7 |
Cilostazol | 1.7 |
DAPT | 20.3 |
Warfarin (%) | 8.4 |
ESA | |
Epoetin α or β (IU/week) | 3204.5 ± 2326.0 |
Darbepoetin α (μg/week) | 40.4 ± 41.2 |
CERA (μg/2 week) | 62.5 ± 17.7 |
Hb (g/dl) | 10.4 ± 1.4 |
Platelet (× 103/μl) | 18.9 ± 6.7 |
PT-INR | 1.0 ± 0.4 |
CRP (mg/dl) | 0.7 ± 1.4 |
Dialysis duration (month) | 28.6 ± 30.9 |
AVF anastomosis type (%) | |
Radiocephalic | 81.4 |
Brachiocephalic | 16.9 |
Radiobasilic | 1.7 |
Quantity of blood flow (ml/min) | 192.3 ± 33.6 |
Flow volume (ml/min) | |
Before VAIVT | 418.7 ± 362.5 |
After VAIVT | 843.3 ± 723.2 |
VAF (%) | |
Stenosis/thrombosis | 15.3/84.7 |
Adverse event (%) | |
Serious bleeding event | |
Intracranial | 0 |
Gastrointestinal | 0 |
CVD event after VAIVT | |
IHD | 11.9 |
CHF | 5.1 |
Stroke | 1.7 |